Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Professor of Medicine
University of California Los Angeles
Director, UCLA CARE Center
Los Angeles, CA

https://www.uclahealth.org/care-center/

https://www.uclahealth.org/ronald-mitsuyasu

http://people.healthsciences.ucla.edu/institution/personnel?personnel_id=8352

Topics of Professional Interest:
  • Clinical trials of novel agents for treatment of AIDS-associated malignancies
  • Role of immune-based therapies in HIV
  • Hematologic abnormalities in HIV
  • Approaches to possible eradication of HIV
  • Gene Therapy in HIV
Current Professional Summary:

Dr Mitsuyasu is Professor of Medicine and Director of the UCLA Center for Clinical AIDS Research and Education at the University of California Los Angeles and Associate Director of Clinical Programs of the UCLA AIDS Institute. He is the Principal Investigator and Group Chair of the AIDS Malignancy Consortium. Dr Mitsuyasu's research focus is on clinical trials of HIV cure approaches, immune-based therapies, vaccines, gene therapies for HIV, and treatments for AIDS-related malignancies and pre-malignant lesions.

Committees and Organizations:
  • Group Chair, AIDS Malignancy Consortium
  • Director, UCLA Center for AIDS Research and Education (CARE Center)
  • Associate Director, UCLA AIDS Institute
Honors and Awards:
  • Fellow, American College of Physicians
  • Clinical Investigator's Award, National Cancer Institute
Education:
  • University of California Berkeley, AB, Biochemistry (1973)
  • University of California Los Angeles, MD (1978)
  • Rush-Presbyterian-St Luke's Medical Center, Residency in Internal Medicine (1978-1981)
  • University of California Los Angeles, Fellowship in Hematology-Oncology (1981-1984)
Selected Publications:
  1. Rudek MA, Moore PC, Mitsuyasu RT, Dezube B, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M, Dowlati A, Little RF, Ivy SP, Deeken JF. A phase I/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy (HAART) in HIV-positive patients with cancer: AIDS Malignancy Consortium Trial AMC 061. Cancer 2014:120 (8);1194-202. PMID:24474568; PMCID:4038645.

  2. Cillo A, Krishnan S, McMahon DK, Mitsuyasu R, Para M, Mellors J. Impact of chemotherapy for HIV-related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy. PLoS One 2014 Mar 17;9(3):e92118. Doi: 10.1371/journal.pone.0092118. eCollection 2014. PMCID:3956871.

  3. Borges AH, Silverberg MJ, Wentworth D, Grulick A, Fitkenheuer G, Mitsuyasu R, Tambussi G, Sabin C, Neaton J, Lundgren JD for INSIGHT, SMART, ESPRIT and SILCAAT Study Groups.  Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS 2013,27:1433-1441. PMID:23945504; PMC4046103

  4. Godbole SV, Nandy K, Gauniyal M, Nalawade P, Sane S, Koyande S, Toyama J, Hegde A, Virgo P, Bhatia K, Paranjape RS, Risbud AR, Mbulaiteye SM, Mitsuyasu RT.  HIV and cancer registry linkage identifies a substantial burden of cancers in persons with HIV in India.  Medicine (Baltimore). 2016 Sep;95(37):e4850. doi: 10.1097/MD.0000000000004850.PMID:2763124

  5. Borges AH, Neuhaus J, Babiker AG, Henry K, Jain MK, Palfreeman A, Mugvenyi P, Domingo O, Hoffman C, Read T, Pujari S, Meulbroek M, Johnson M, Wilkin T, Mitsuyasu R.  Immediate antiretroviral therapy initiation reduces risk of infection-related cancer in early HIV infection. Clin Infect Dis. 2016 Dec 15;63(12):1668-1676.  PMID: 27609756; PMCID: PMC5146718.

  6. Epeldegui M, Lee J, Martinez AC, Widney DP, Magpantay L, Regidor D, Mitsuyasu R, Sparano JA, Ambinder A, Martinez-Maza O. Predictive value of cytokines and immune activation biomarkers in AIDS-related non-Hodgkin lymphoma treated with rituximab plus infusional EPOCH (AMC-034 trial), Clin Cancer Res 2016 Jan 15:22(2):328-36. Doi: 10.1158/1078-0432.CCR-14-0466. PMID:26384320 PMCID:PMC4715998

  7. Lee, J, Dhakal I, Corey C, Noy A, Haigentz M, Palfesky J, Krown S, Ambinder R, Mitsuyasu, R. Risk of Cancer Among Commercially Insured HIV-infected Adults on Antiretroviral Therapy. J Cancer Epidemiology 2016:2138259. PMID:27882054; PMCID: PMC5110893.

  8. Sparano JA, Lee JY, Palefsky J, Henry DH, Wachsman W, Rajdev L, Aboulafia D, Ratner L, Fitzgerald TJ,, Kachnic L, Mitsuyasu R.  Cetuximab plus chemoradiotherapy for human immunodeficiency virus-associated anal carcioma: A phase II AIDS Malignancy Consortium trial (AMC 045). J Clin Onc 2016 Dec 12: JCO 2016691642.(Epub ahead of print). PMID: 27937092.

  9. Polizotto MN, Mitsuyasu RT.  Clinical and scientific challenges in HIV-associated malignancies. Curr Opin HIV AIDS.2017  January 2017, 12(1):1-5. PMID:27763914.

Presentations

Improving the Management of HIV Disease®: An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management

An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management

An Advanced CME Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management